Page last updated: 2024-10-25

dantrolene and Subarachnoid Hemorrhage

dantrolene has been researched along with Subarachnoid Hemorrhage in 12 studies

Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.

Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.

Research Excerpts

ExcerptRelevanceReference
"In this pilot study, a single dose of intravenous dantrolene in cerebral vasospasm after subarachnoid hemorrhage appears feasible while inhibiting vasoconstriction in the low-dose group, but it may lower blood pressure."9.15Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study. ( Muehlschlegel, S; Rordorf, G; Sims, J, 2011)
"Dantrolene is a promising new therapeutic agent in the treatment of cerebral vasospasm."6.82The Role of Parenteral Dantrolene in the Contemporary Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. ( Nunna, RS; Ortiz, M; Qureshi, AI; Ravipati, K; Siddiq, F; Tran, A, 2022)
"Dantrolene has a safe side-effect profile and a mechanism of action that makes it attractive as an option for treatment of cerebral vasospasm."5.51Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage. ( Jahngir, M; Litofsky, NS; Nattanmai, P; Ortiz Torres, MJ; Qualls, K; Qureshi, AI, 2019)
"We report a case of refractory cerebral vasospasm treated with intra-arterial dantrolene after aneurysmal subarachnoid hemorrhage."5.38Intra-arterial dantrolene for refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage. ( Grigoryan, M; Majidi, S; Qureshi, AI; Tekle, WG, 2012)
"In this pilot study, a single dose of intravenous dantrolene in cerebral vasospasm after subarachnoid hemorrhage appears feasible while inhibiting vasoconstriction in the low-dose group, but it may lower blood pressure."5.15Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study. ( Muehlschlegel, S; Rordorf, G; Sims, J, 2011)
"In New Zealand white rabbits (N = 22), vasospasm was individually provoked through experimentally induced subarachnoid hemorrhage and confirmed via conventional angiography, grouping animals by IA-infused drug (nicardipine vs."4.12Comparative Study of Vasodilatation After Intra-arterial Nicardipine or Dantrolene Infusion in Animal Model of Cerebral Vasospasm. ( Byoun, HS; Cho, YD; Lim, J, 2022)
"Dantrolene is a promising new therapeutic agent in the treatment of cerebral vasospasm."2.82The Role of Parenteral Dantrolene in the Contemporary Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. ( Nunna, RS; Ortiz, M; Qureshi, AI; Ravipati, K; Siddiq, F; Tran, A, 2022)
" Three patients in the IV-D versus two in the placebo group had severe adverse events possibly attributable to infusion and reached stop criteria: one IV-D patient developed liver toxicity; two patients in each group developed brain oedema requiring osmotherapy."2.80Dantrolene for cerebral vasospasm after subarachnoid haemorrhage: a randomised double blind placebo-controlled safety trial. ( Barton, B; Carandang, R; Flood, TF; Garland, B; Gounis, MJ; Hall, W; Izzy, S; Kini, N; Muehlschlegel, S; Ouillette, C; van der Bom, IM; Wakhloo, AK; Weaver, JP, 2015)
" Dose-response curves for the 5-HT-induced contraction (from 0."1.62The combination of dantrolene and nimodipine effectively reduces 5-HT-induced vasospasms in diabetic rats. ( Crespo, MJ; García, L; Morales, M; Román, M, 2021)
"Dantrolene has a safe side-effect profile and a mechanism of action that makes it attractive as an option for treatment of cerebral vasospasm."1.51Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage. ( Jahngir, M; Litofsky, NS; Nattanmai, P; Ortiz Torres, MJ; Qualls, K; Qureshi, AI, 2019)
"We report a case of refractory cerebral vasospasm treated with intra-arterial dantrolene after aneurysmal subarachnoid hemorrhage."1.38Intra-arterial dantrolene for refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage. ( Grigoryan, M; Majidi, S; Qureshi, AI; Tekle, WG, 2012)
"According to the diagnostic criteria for malignant hyperthermia by Larach and his colleague, malignant hyperthermia was somewhat less than likely in our case."1.33[Central hyperthermia suspected of malignant hyperthermia in a patient undergoing radical neck clipping for cerebral aneurysm]. ( Matsuki, A; Murakawa, T; Sakai, I, 2005)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's4 (33.33)24.3611
2020's6 (50.00)2.80

Authors

AuthorsStudies
Ortiz, M2
Nunna, RS1
Ravipati, K1
Tran, A1
Qureshi, AI3
Siddiq, F1
Lim, J1
Cho, YD1
Byoun, HS1
Crespo, MJ2
Román, M2
Tirado, G1
Martins, AH1
Ferrer-Acosta, Y1
Martinez-Jimenez, SM1
Bongetta, D1
De Pirro, A1
Iotti, GA1
Assietti, R1
Jahngir, M2
Qualls, K2
Litofsky, NS2
Nattanmai, P2
Qureshi, A1
García, L1
Morales, M1
Ortiz Torres, MJ1
Muehlschlegel, S3
Carandang, R1
Hall, W1
Kini, N1
Izzy, S1
Garland, B1
Ouillette, C1
van der Bom, IM1
Flood, TF1
Gounis, MJ1
Weaver, JP1
Barton, B1
Wakhloo, AK1
Rordorf, G2
Bodock, M1
Sims, JR1
Sims, J1
Majidi, S1
Grigoryan, M1
Tekle, WG1
Murakawa, T1
Sakai, I1
Matsuki, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Dantrolene in the Prevention and Treatment of Cerebral Vasospasm in Subarachnoid Hemorrhage[NCT01024972]Phase 1/Phase 231 participants (Actual)Interventional2009-10-31Completed
Dantrolene in the Treatment of Cerebral Vasospasm After Subarachnoid Hemorrhage - a Phase 1 Study[NCT00964548]Phase 1/Phase 210 participants (Actual)Interventional2007-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hyponatremia

Number of subjects who developed hyponatremia (sNa ≤132mmol/L) (NCT01024972)
Timeframe: Seven days

Interventionparticipants (Number)
Dantrolene7
Placebo10

In-hospital Mortality

Number of subjects who expired during hospitalization. (NCT01024972)
Timeframe: up to 90 days

Interventionparticipants (Number)
Dantrolene2
Placebo1

Liver Toxicity

Number of subjects who developed liver toxicity as evidenced by Liver Function Test elevation greater than 5 times the upper limit of normal. (NCT01024972)
Timeframe: 7 days

Interventionparticipants (Number)
Dantrolene1
Placebo0

Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion)

Systolic Blood Pressure (Change from baseline systolic blood pressure (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion

InterventionmmHg (Mean)
Dantrolene (Low Dose)-8
Dantrolene (High Dose)-3.4

Transcranial Doppler Mean Flow Velocity (Change From Baseline Mean Flow Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)

Mean flow velocities of vessel in vasospasm (Change from baseline mean flow velocity (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion

Interventioncm/s (Mean)
Dantrolene (Low Dose)-18
Dantrolene (High Dose)-13

Transcranial Doppler Peak Systolic Velocity (Change From Baseline Peak Systolic Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)

Peak Systolic Velocity of vessel in vasospasm (Change from baseline peak systolic velocity (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion

Interventioncm/s (Mean)
Dantrolene (Low Dose)-30
Dantrolene (High Dose)-26

Reviews

1 review available for dantrolene and Subarachnoid Hemorrhage

ArticleYear
The Role of Parenteral Dantrolene in the Contemporary Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review.
    World neurosurgery, 2022, Volume: 161

    Topics: Animals; Dantrolene; Humans; Prospective Studies; Retrospective Studies; Subarachnoid Hemorrhage; Va

2022

Trials

2 trials available for dantrolene and Subarachnoid Hemorrhage

ArticleYear
Dantrolene for cerebral vasospasm after subarachnoid haemorrhage: a randomised double blind placebo-controlled safety trial.
    Journal of neurology, neurosurgery, and psychiatry, 2015, Volume: 86, Issue:9

    Topics: Adult; Aged; Dantrolene; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscle Relaxants, C

2015
Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study.
    Stroke, 2011, Volume: 42, Issue:5

    Topics: Adult; Blood Pressure; Dantrolene; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hu

2011
Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study.
    Stroke, 2011, Volume: 42, Issue:5

    Topics: Adult; Blood Pressure; Dantrolene; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hu

2011
Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study.
    Stroke, 2011, Volume: 42, Issue:5

    Topics: Adult; Blood Pressure; Dantrolene; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hu

2011
Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study.
    Stroke, 2011, Volume: 42, Issue:5

    Topics: Adult; Blood Pressure; Dantrolene; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hu

2011

Other Studies

9 other studies available for dantrolene and Subarachnoid Hemorrhage

ArticleYear
Comparative Study of Vasodilatation After Intra-arterial Nicardipine or Dantrolene Infusion in Animal Model of Cerebral Vasospasm.
    Clinical neuroradiology, 2022, Volume: 32, Issue:4

    Topics: Animals; Dantrolene; Models, Animal; Nicardipine; Rabbits; Subarachnoid Hemorrhage; Vasospasm, Intra

2022
Dantrolene Significantly Improves Cerebral Blood Flow in a Rat Model of Hemorrhagic Vasospasms.
    Pharmacology, 2023, Volume: 108, Issue:3

    Topics: Animals; Cerebrovascular Circulation; Dantrolene; Nimodipine; Rats; Rats, Sprague-Dawley; Subarachno

2023
Letter to the Editor Regarding "Intraarterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage": Is Malignant Hyperthermia a Model for Showing Dantrolene Efficacy in Limiting Brain Damage?
    World neurosurgery, 2020, Volume: 133

    Topics: Brain; Dantrolene; Humans; Malignant Hyperthermia; Subarachnoid Hemorrhage; Vasospasm, Intracranial

2020
In Reply to the Letter to the Editor Regarding "Intra-arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage".
    World neurosurgery, 2020, Volume: 143

    Topics: Cerebral Angiography; Dantrolene; Humans; Infusions, Intra-Arterial; Subarachnoid Hemorrhage; Vasosp

2020
The combination of dantrolene and nimodipine effectively reduces 5-HT-induced vasospasms in diabetic rats.
    Scientific reports, 2021, 05-10, Volume: 11, Issue:1

    Topics: Animals; Calcium Channel Blockers; Dantrolene; Diabetes Mellitus, Experimental; Drug Therapy, Combin

2021
Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage.
    World neurosurgery, 2019, Volume: 125

    Topics: Adult; Dantrolene; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Muscle Relaxants, Central

2019
Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series.
    Neurocritical care, 2009, Volume: 10, Issue:1

    Topics: Adult; Dantrolene; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Muscle Relaxants, Cent

2009
Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series.
    Neurocritical care, 2009, Volume: 10, Issue:1

    Topics: Adult; Dantrolene; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Muscle Relaxants, Cent

2009
Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series.
    Neurocritical care, 2009, Volume: 10, Issue:1

    Topics: Adult; Dantrolene; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Muscle Relaxants, Cent

2009
Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series.
    Neurocritical care, 2009, Volume: 10, Issue:1

    Topics: Adult; Dantrolene; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Muscle Relaxants, Cent

2009
Intra-arterial dantrolene for refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
    Neurocritical care, 2012, Volume: 17, Issue:2

    Topics: Angioplasty, Balloon; Anterior Cerebral Artery; Cerebral Angiography; Dantrolene; Female; Humans; In

2012
[Central hyperthermia suspected of malignant hyperthermia in a patient undergoing radical neck clipping for cerebral aneurysm].
    Masui. The Japanese journal of anesthesiology, 2005, Volume: 54, Issue:1

    Topics: Anesthesia, General; Creatine Kinase; Dantrolene; Diagnosis, Differential; Female; Fever; Humans; Hy

2005